Objectives: To retrospectively evaluate the impact on daily activities of transcatheter closure of patent foramen ovale (PFO) versus medical therapy in patients with migraine and to analyze the role of the residual shunt after PFO closure. Background: While non-controlled observational studies reported an improvement of migraine after PFO closure, a randomized trial has shown no benefit of such an intervention. The role of residual shunt after PFO closure is also poorly known. Methods: Out of 217 patients with migraine and echocardiographic evidence of PFO, 89 were managed with percutaneous PFO closure (Group A) while 128 were medically treated (Group B). All MIDAS questionnaires were obtained at the first evaluation and repeated at least 6 months after the index evaluation or after the PFO closure. All the patients were also asked to give a subjective estimate of their migraine status. A postprocedural transcranial Doppler study was available in 70 patients in Group A. Results: The mean basal MIDAS score did not differ between the two groups (p = 0.859). After a mean follow-up (FU) of 1399 ± 982 days the MIDAS score decreased significantly in both groups (Group A baseline vs FU, p < 0.001; Group B baseline vs FU, p < 0.001), but no differences were observed between groups (p = 0.204). However a significantly higher number of Group A patients reported a perceived clinical benefit or the disappearance of migraine compared to Group B (p < 0.001). Patients with moderate or severe residual right to left shunt were no more likely to have an higher MIDAS score or to complain of migraine than those with mild or no shunt. Conclusions: Although the overall evolution of migraine is not significantly different, the abolition of migraine occurs in a larger proportion after PFO closure.
Introduction
Migraine affects more than 10% of the general population and is associated with significant morbidity, loss of productivity and high health care costs [1] . A causal relationship has been hypothesized between patent foramen ovale (PFO) and migraine based on the evidence that a PFO can be found in nearly half the sufferers of migraine with aura [2] [3] [4] , and that the prevalence of migraine in stroke patients with PFO is high, ranging between 27% and 52% [5] [6] [7] . After the initial report by Wilmshurst et al. [8] , many other non-controlled observational studies have described an improvement of migraine after PFO closure [9] [10] [11] [12] [13] [14] [15] [16] . However, the MIST study, a randomized, double blind, shame procedure controlled trial, did not show any benefit of PFO closure in terms of cessation or reduction of episodes, severity of attacks, and change in the characteristics of migraine [17] . Moreover, a recent review by Sathasivam and Sathasivam stated that currently PFO closure cannot be recommended as a routine treatment for migraine for the debatable pathophysiological relevance, the inconclusively proven http://dx.doi.org/10.1016/j.jjcc.2014.02.023 0914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology. efficacy and the possible complication related to PFO occlusion, highlighting the need for further research in this field [18] .
The purpose of our study was to retrospectively evaluate the impact of PFO closure vs standard medical therapy on migraine severity. Since the effect of residual shunt after PFO closure is controversial [10, 17] , we also analyzed the relationship between the residual shunt after percutaneous PFO closure and the evolution of the disease in migraineurs.
Materials and methods

Patients selection
Between December 1999 and June 2012, of 835 patients referred to our outpatient clinic for PFO-related conditions, 217 patients fulfilled the following inclusion criteria:
-clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders [19] , and -echocardiographic evidence of PFO.
The primary referral diagnosis was migraine with or without aura in 148 (68.2%), stroke in 42 (19.3%), transient ischemic attack (TIA) in 24 (11.1%), and peripheral embolism in 3 (1.4%).
Clinical and echocardiographic work-up
A detailed history of symptoms and drug therapy, a complete physical examination, and a transthoracic and transesophageal echocardiogram (TEE) to confirm the diagnosis of PFO was obtained in all patients. All shunt evaluations were made with a multiplane TEE probe using agitated saline solution as a contrast agent. A PFO with RLS (spontaneous or during Valsalva maneuver) was defined as the passage of at least five microbubbles from the right to the left atrium across the interatrial septum within three cardiac cycles from intravenous saline injection. An atrial septal aneurysm defined as a flapping movement of the interatrial septum during the cardiac cycle with an excursion ≥1 cm was evident in 29 out of 89 subjects (32.5%) who underwent a percutaneous occlusion. After PFO closure, power M-mode transcranial color Doppler (TCD) scanning performed through the temporal approach after agitated saline injection was used as a screening technique to assess the presence and degree of the residual RLS. The shunt on TCD was graded as absent or mild [0-10 Micro Embolic Signals (MES)], moderate (>10 MES up to a shower or curtain pattern only after Valsalva), severe (basal shower or curtain pattern).
Evaluation of migraine
Migraine severity was estimated in all patients at baseline using the validated Migraine Disability Assessment Questionnaire (MIDAS) score [20] . In brief this five-point questionnaire evaluates the burden of migraine episodes in the past 3 months, their impact on working, social, leisure and family activities and the perceived pain.
Management strategies
After a thorough explanation and discussion with the patients of knowns and unknowns concerning the risk-benefit ratio of PFO closure vs medical therapy, PFO closure was recommended to 89 patients (Group A), while the remaining 128 were advised to carry on the medical treatment (Group B). More in detail we proposed PFO closure in patients with migraine associated with previous suspected paradoxical embolic events, while closure was proposed to "pure migraineurs" without history of previous paradoxical embolism only in the case of severely disabling symptoms not controlled by multiple therapy. Migraine associated with disabling symptoms and refractory to conventional medical therapy was the only reason to recommend PFO closure in 35 patients.
In the remaining 54 the primary referral diagnosis was a cerebral or peripheral embolic event (Table 1) .
Percutaneous closure of PFO
Under local anesthesia, through a femoral venous access, the PFO was crossed with a multipurpose catheter. An exchange guidewire was then advanced to the left superior pulmonary vein. A long sheath was then advanced into the left atrium and the device was implanted and released under fluoroscopic guidance in a 50-60 • left anterior oblique projection. Devices implanted are listed in Table 2 . Neither transesophageal nor intracardiac echocardiography was routinely employed. All procedures were free of acute complications, in particular none of the patients experienced serious bleeding requiring transfusion. Discharge therapy consisted of aspirin 100 mg daily for 6 months and clopidogrel 75 mg daily for Bold is used to highlight statistically significant parameters. 3 months. Infectious endocarditis prophylaxis was also advised for six months.
Follow up
All patients were seen at 6 and 12 months and yearly thereafter. Follow-up time was defined as the time interval between the first clinical evaluation and the date of the last available follow-up visit. A repeated MIDAS questionnaire was obtained 6 months after the first evaluation or transcatheter closure of PFO. We also evaluated the subjective perceived benefit by asking the patients whether they felt better, unchanged or worse compared to the first assessment. Seventy of the 89 patients who underwent percutaneous closure had a TCD study repeated 6 months after the procedure to assess the presence of a residual shunt.
Statistical analysis
Descriptive analysis was performed using mean ± standard deviation for continuous variables and counts and percentages for non-continuous variables. The normality of distribution of continuous variables was evaluated by the Kolmogorov-Smirnov test, and therefore compared with independent sample Student t, one way ANOVA or uncorrected chi square method when appropriate. All probability values were considered to be significant at a value ≤0.05.
Results
The baseline characteristics of study subjects are reported in Table 1 . While age was similar, there were more women in Group B.
Patients who underwent PFO closure had more frequently a history of presumed paradoxical embolism and suffered from migraine with aura compared to Group B. The MIDAS score did not differ between two groups. A larger proportion of Group A subjects were not taking any therapy. They also consumed a lower amount of drugs per month, compared to group B. Among group A patients a lower MIDAS score was evident in subjects with history of cerebral or peripheral embolism if compared to pure migraineurs (34.5 ± 40.8 vs 67.5 ± 90.1; p < 0.001).
After a mean follow-up 1399 ± 982 days, a significant reduction of the MIDAS score was observed in both groups (Group A 47.5 ± 66.3 vs 17.2 ± 33.8; p < 0.001; and Group B 46.1 ± 49.6 vs 26.3 ± 38.2; p < 0.001), but no differences were observed between groups (p = 0.204; Table 3 ).
A subjective improvement was perceived by both Group A and B patients, but the percentage of subjects who reported a benefit was greater in the group who had their PFO closed compared to those in medical therapy (83.1% vs 51.6%; p < 0.001; Table 3 ).
Migraine disappeared in 46 (51.6%) out of 89 patients with PFO closed and only in 31 (24.2%) out of 128 patients who continued with medical treatment (p < 0.001). The evolution of migraine according to the presence/absence of aura is reported in Table 3 .
A change in the pattern of drug therapy was also observed ( Table 3) . A substantial proportion of patients discontinued all therapy in both groups: almost half of Group A patients were not taking any medication compared to one out of four Group B patients.
Postprocedural TCD was available for 70 patients: RLS was absent or mild in 54, moderate in 13 and severe in 3. In two of these three latter patients, TEE was negative; since they had a very little or no migraine left, no further intervention was recommended. In the remaining patient, because TEE confirmed a substantial residual shunt, a second cardiac catheterization was performed. No residual shunt was found across the interatrial septum or the device both by conventional cavography and by contrast echocardiography with injection in the inferior caval vein. However, the injection of echocontrast directly into the pulmonary artery revealed a transpulmonary shunt.
In our population, the presence of ASA was not associated with a moderate or severe residual shunt (p = 0.541).
The proportion of patients with MIDAS score > 20 was not significantly different among subjects with different degrees of residual shunts (Fig. 1) . The percentage of subjects who perceived a benefit after PFO closure was not different in patients with no or mild (85.0%) compared with those with moderate or severe (87.5%) Table 3 Follow-up data.
Interventional (Group A)
Medical Tx (Group B) P value residual shunt (p = 0.961; Fig. 2 ). Even at follow-up, in Group A subjects a significantly lower MIDAS score was evident in patients treated for the secondary prevention of paradoxical embolism if compared to pure migraineurs (MIDAS score 13.2 ± 26.89 vs 23.25 ± 41.99; p = 0.009). Among those patients 27 out of 35 (77.1%) pure migraineurs and 47 out of 57 patients with migraine associated with embolic event reported a subjective improvement of the migraine after intervention (p = 0.224).
Patients whose migraine became worse after PFO closure were all females with an age between 37 and 48 years, three out of five had migraine with aura, while the remaining referred only migraine, in all but one the postprocedural TCD was negative, excluding a possible deterministic role of PFO.
During follow-up no deaths or strokes were observed. In Group A one patient who had previous history of paradoxical embolism associated with migraine underwent surgical removal of the device due to endocarditis, while in Group B one patient experienced a transient ischemic attack during an episode of palpitations and thus was implanted with a loop recorder for the suspect of paroxysmal episodes of atrial fibrillation.
Discussion
Since the first observation of Wilmhshurst et al. in 2000 [8] , a number of retrospective studies reported a significant reduction in migraine burden after percutaneous PFO closure [9] [10] [11] [12] [13] . The case control study by Anzola et al. [14] also found an overall improvement of migraine severity. However, the MIST trial [17] , which was a randomized, sham controlled study, failed to demonstrate a definite superiority of PFO closure on migraine cessation or change in severity. Nevertheless, even in this negative study a few patients reported the complete resolution of their migraine.
We found that a significant reduction of the burden of migraine and of its impact on work, social and leisure activities occurred both in patients who had the PFO closed and in those who continued with medical treatment at a relatively long follow-up interval. The MIDAS score was not different between the two groups. However, the number of patients in whom migraine disappeared was significantly higher in Group A than in Group B patients.
Also, when asked whether they felt better, worse or unchanged, the patients who had their PFO closed were more likely to consider themselves better than those on medical therapy alone.
Our work cannot ultimately resolve the issues of the spontaneous changes in the natural history of migraine [20, 21] and of a possible placebo effect, which is known to reduce the frequency of migraine by up to 70% [19] .
We concur with the results of the MIST trial; in that the presence and degree of a residual shunt do not correlate with the evolution of migraine.
Limitations
The retrospective nature of our work may have introduced patient and treatment selection biases.
Moreover the presence of a heterogeneous population in terms of previous central or peripheral embolisms may influence the results.
Conclusions
Our data suggest that the evolution of migraine is not predictably influenced by transcatheter PFO closure when compared with medical treatment. However, many patients do report a significant improvement after PFO closure or the complete resolution of migraine. This suggests that a percentage of migraineurs may benefit from an interventional strategy. Unfortunately, capable tools to select a priori this population are still lacking. Finally, the presence of residual shunt is not associated with a worse evolution of migraine after PFO closure.
